CrossAssetDataThe Company File
···
John Bausch and Henry Lomb, New York State Men Biographic Studies and Character Portraits (1910)
Picture: The Argus Company, Public domain, via Wikimedia Commons
BLCO

Bausch + Lomb Corporation

Bausch + Lomb Corporation is classed by the SEC under Ophthalmic Goods (industry code 3851), based in Vaughan, ON. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $5.1 billion and a loss of $360 million (its filed statements).

Product business Ophthalmic Goods Vaughan, ON filings since 2021 9 of 9 filed
Ask the desk about BLCO → Compare BLCO with COO → Price chart on TradingView ↗ Full EDGAR file ↗ Watch BLCO →

Sector peers: COOALCEYEWRBY

4.9/10headline grade
vs its business-model standard
5.6/10past 5.2/10present 3.7/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3851, Ophthalmic Goods); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 4.9 out of ten, 9 of 9 metrics filed: past 5.6 out of ten, present 5.2 out of ten, future 3.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 6.9 out of ten. No warning events in its filings since 2021. 69th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 6.3 out of ten. +8.4% a year over 6 filed years; profitable in 2 of 6. 63rd percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 2.6 out of ten. Share count grew 0.3% a year. 0% of cash flow returned. Insiders: 3 sales, 9 purchases. 26th percentile among 5 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 4.4 out of ten. ROE -6%: lost 6¢ per shareholder dollar. Leverage 54%: owes 54¢ per asset dollar. 44th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.0 out of ten. top 40% of 8 in its family; net margin -7.1%. 60th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.5 out of ten. top 45% of 6 in its family for leadership; chief executive since 2023. 55th percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 2.5 out of ten. bottom 25% of 8 in its family for room to expand. 25th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 6.4 out of ten. top 36% of 8 in its family for growth drivers. 64th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 2.3 out of ten. bottom 23% of 8 in its family for expectations against reality. 23rd percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-18 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-29 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-29 (on EDGAR). Newest filing: Form 144, 2026-09-28. Filings on record since 2021. Read from EDGAR 2026-10-12.

Where the revenue comes from

Lines of business in fiscal 2025: Vision Care 57%, Pharmaceuticals 25%, Surgical 18%. By geography: U.S. and Puerto Rico 50%, Other 15%, China 7%, France 5%, Japan 4%, Germany 3%. As tagged in its annual report (Form 10-K, filed 2026-02-18).

Who runs it

Saunders, Brent L (Chairman of the Board and CEO); Bonnefoy, Luc (President, Surgical); Stewart, Andrew J. (President, GPIC); Eldessouky, Sam (EVP and CFO); Bailey, A Robert D (EVP & Chief Legal Officer); Munsch, Frederick (SVP, Controller and CAO); Hashad, Yehia (EVP of R&D and CMO); Appio, Thomas (director); Chersi, Robert J (director); Paul, Laurence E (director); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.